Table 8.
Multivariate analysis of comorbidity in COPD patients
| Variable | Estimate | Std. Error | P Value | OR | Lower | Upper |
|---|---|---|---|---|---|---|
| Age | 0.678 | 0.459 | 0.140 | 1.970 | 0.803 | 4.923 |
| Gender | 1.296 | 0.767 | 0.091 | 3.656 | 0.854 | 17.772 |
| COPD Duration (years) | 0.537 | 0.386 | 0.164 | 1.711 | 0.818 | 3.758 |
| Smoking History | 0.876 | 0.513 | 0.088 | 2.401 | 0.891 | 6.765 |
| Corticosteroid Treatment | -0.947 | 0.587 | 0.107 | 0.388 | 0.117 | 1.193 |
| GOLD Classification | -1.667 | 0.422 | 0.001 | 0.189 | 0.078 | 0.414 |
| IL-17 | 0.690 | 0.459 | 0.133 | 1.994 | 0.812 | 4.974 |
| IL-33 | 3.355 | 0.606 | 0.001 | 28.631 | 9.562 | 105.676 |
| FVC | 0.263 | 0.671 | 0.696 | 1.301 | 0.360 | 5.177 |
| RV | 1.667 | 0.538 | 0.002 | 5.299 | 1.903 | 16.035 |
| RV/TLC | 1.781 | 0.571 | 0.002 | 5.937 | 2.018 | 19.474 |
Note: IL-17: Interleukin-17, IL-33: Interleukin-33, FVC: Forced Vital Capacity, RV: Residual Volume, RV/TLC%: RV to TLC Ratio, COPD: Chronic Obstructive Pulmonary Disease, GOLD: Global Initiative for Chronic Obstructive Lung Disease.